EMA’s Thomas Lönngren joins market access firm
pharmafile | January 19, 2011 | News story | Research and Development, Sales and Marketing | NDA Group, Thomas Lönngren, appointment, recruitment, research and development, sales and marketing
The former head of the EMA Thomas Lönngren has taken up a post at new European regulatory and market access business the NDA Group.
The firm aims to help reduce billions in wasted drug development costs, ensure the correct new medicines get to market faster and improve pharma’s performance.
Lönngren was previously executive director of European regulator the EMA and will take a strategic advisory role in the new business.
“I’ve recognised for a long time that the whole area of market access needs new ideas and a new vision. I plan to further develop my ideas surrounding international regulatory strategies, coupled with pushing for a joined-up approach to HTA, to enable the best medicines to reach needy patients as efficiently as possible,” he said.
Lönngren has 30 years experience in the regulatory field and spent the last 10 years heading-up the EMA.
NDA chief executive Dr Lars-Helge Strömquist said: “Thomas Lönngren has had a pivotal role within the European drug regulatory system and has been recognised internationally as a key influencer in the pharmaceutical sector. His reputation and vision will be a tremendous asset to NDA and to our customers.”
Independent consulting group NDA is based in the UK and has offices in Germany and Sweden. It aims to support European pharmaceutical businesses as well as global organisations looking to launch new medicines in Europe.
“The route to market is extremely complex and expensive and many products fail because companies do not fully address the needs to demonstrate the quality, safety and efficacy of their products and also adapting to the European reimbursement systems,” said Tony Baker, vice president, the NDA Group.
“Many new drug developments terminate before they even reach the regulators. And even if a product gains approval, the industry faces great challenges over pricing and reimbursement from regional agencies. This prevents many potential groundbreaking medicines from ever reaching patients.”
Dominic Tyer
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
